Scarica l'app Stockscreener
1.02
11.30%
-0.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.15
Aprire:
$1.08
Volume 24 ore:
630
Relative Volume:
11.54
Capitalizzazione di mercato:
$N/A
Reddito:
$3.13M
Utile/perdita netta:
$-40.29M
Rapporto P/E:
-0.3188
EPS:
-3.2
Flusso di cassa netto:
$-33.08M
1 W Prestazione:
-11.30%
1M Prestazione:
-60.53%
6M Prestazione:
+427.32%
1 anno Prestazione:
+221.67%
Intervallo 1D:
$1.02
$1.08
Intervallo di 1 settimana:
$1.02
$1.08
Portata 52W:
$1.02
$1.15
Trevena Inc Stock (TRVN) Company Profile
Confronta TRVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRVN
Trevena Inc
|
1.02 | 0 | 3.13M | -40.29M | -33.08M | -3.20 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.34 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Trevena Inc Stock (TRVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-15 | Iniziato | Oppenheimer | Perform |
| 2020-09-14 | Iniziato | Guggenheim | Buy |
| 2020-08-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-05-31 | Ripresa | H.C. Wainwright | Buy |
| 2018-11-05 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-10-12 | Downgrade | Needham | Buy → Hold |
| 2018-10-10 | Downgrade | Jefferies | Buy → Hold |
| 2017-11-08 | Reiterato | Needham | Buy |
| 2017-10-16 | Downgrade | Barclays | Overweight → Equal Weight |
| 2017-10-12 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-08 | Reiterato | Needham | Buy |
| 2017-02-23 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-22 | Reiterato | FBR & Co. | Outperform |
| 2017-02-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-01-09 | Iniziato | H.C. Wainwright | Buy |
| 2017-01-05 | Iniziato | Oppenheimer | Outperform |
| 2016-05-17 | Reiterato | FBR Capital | Outperform |
| 2016-05-17 | Reiterato | Needham | Buy |
| 2016-03-29 | Iniziato | FBR Capital | Outperform |
| 2015-09-01 | Reiterato | Wedbush | Outperform |
| 2015-08-03 | Iniziato | Brean Capital | Buy |
Mostra tutto
Trevena Inc Borsa (TRVN) Ultime notizie
TREVENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Trevena, Inc. To Contact The Firm - ACCESS Newswire
Acute Pain Drug Pipeline Analysis: Market Overview, Trends, and Future Growth (2034) - openPR.com
Trevena to Present at the H.C. Wainwright Global Investment Conference - The Globe and Mail
Opioid Drugs Market in 2025-2032 Detailed Study Analysis with - openPR.com
Financial Comparison: Adicet Bio (NASDAQ:ACET) & Trevena (NASDAQ:TRVN) - Defense World
Trevena (TRVN) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws; Investors Who Suffered Losses Exceeding $50,000 Encouraged to Contact the Firm - ACCESS Newswire
COVID-19 Therapeutics Market Current Scenario with Future Aspect Analysis - openPR.com
Opioid Drugs Market: Investment Analysis & Growth Opportunity - openPR.com
Highest-Paid CEOs2024 - AFL-CIO
Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com - Defense World
Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com
Block & Leviton Files Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire
Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com - Defense World
Aviation Co. Says Workers' Class Action Too Broad - Law360
Block & Leviton Reminds Shareholders of Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN) - Defense World
Trevena (NASDAQ:TRVN) Stock Crosses Below 200 Day Moving Average – Time to Sell? - Defense World
Opioid Drugs Market Detailed In New Research Report 2025-2032 | - openPR.com
Trevena Delays Yearly Report Filing - TipRanks
Trevena (TRVN) Expected to Announce Quarterly Earnings on Monday - Defense World
Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V - The Manila Times
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - The Manila Times
Global Post Operative Pain Management Market Advancements Highlighted by Forecast: Key Growth Drivers, Tren... - WhaTech
Ten option delistings on March 24th - TipRanks
Trevena (NASDAQ:TRVN) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN) - The AM Reporter
Opioid Drugs Market to Witness Remarkable Growth with Johnson & Johnson, Endo International plc - openPR
Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com - Defense World
Trevena, Inc. to Host Earnings Call - ACCESS Newswire
Trevena (NASDAQ:TRVN) Now Covered by StockNews.com - Defense World
Opioid Drugs Market Growth, Demand Trends, Size & Competitive - openPR
Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com - Defense World
Promising Automotive Stocks To Keep An Eye On – February 04th - ETF Daily News
Trevena Announces Board and Executive ChangesOn January 31, 2025, Trevena, Inc. (NASDAQ:TRVN) filed a Form 8-K with the Securities and Exchange Commission, detailing significant departures and appointments within the company.In line with ongoin - Defense World
Trevena Implements Cost-Cutting Measures Amid Leadership Changes - TipRanks
Trevena (NASDAQ:TRVN) Shares Cross Below 200 Day Moving Average – Time to Sell? - Defense World
Trevena discontinues OLINVYK injection sales By Investing.com - Investing.com Canada
Trevena discontinues OLINVYK injection sales - Investing.com
Trevena (NASDAQ:TRVN) Stock Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com - Defense World
Trevena Announces FDA Acceptance For Review Of New Drug Application For OLINVO(Oliceridine) Injection - Reuters.com
Trevena Inc Azioni (TRVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
2.33%
Capitalizzazione:
|
Volume (24 ore):